

Oskar Hansson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1661466/oskar-hansson-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

484
papers

26,071
citations

85
h-index

144
g-index

564
ext. papers

34,124
ext. citations

7.2
avg, IF

7.3
L-index

#	Paper	IF	Citations
484	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. <i>Lancet Neurology, The</i> , 2006 , 5, 228-34	24.1	1254
483	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93	27.4	758
482	Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. <i>Neuron</i> , 2002 , 33, 849-60	13.9	506
481	Cerebrospinal fluid levels of Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. <i>Archives of General Psychiatry</i> , 2012 , 69, 98-106		459
480	Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. <i>Biological Psychiatry</i> , 2009 , 66, 287-92	7.9	361
479	Earliest accumulation of Amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017 , 8, 1214	17.4	348
478	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <i>Archives of Neurology</i> , 2010 , 67, 949-56		344
477	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. <i>Archives of Neurology</i> , 2012 , 69, 1445-52		327
476	Amyloid biomarkers in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 297-309	13.2	320
475	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017 , 16, 661-676	24.1	308
474	Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 13924-9	11.5	297
473	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020 , 26, 379-386	50.5	292
472	Plasma Amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016 , 6, 26801	4.9	290
471	Improving the survival of grafted dopaminergic neurons: a review over current approaches. <i>Cell Transplantation</i> , 2000 , 9, 179-95	4	287
470	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology, The</i> , 2020 , 19, 422-433	24.1	286
469	Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. <i>Diabetes</i> , 2012 , 61, 3322-32	0.9	274
468	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016 , 87, 1827-1835	6.5	269

467	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 772-781	27.4	268
466	CSF biomarkers of Alzheimer's disease concord with amyloid-IPET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1470-1481	1.2	266
465	Plasma tau levels in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 9	9	262
464	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. <i>Nature Medicine</i> , 1999 , 5, 97-100	50.5	258
463	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β amyloid 42: a cross-validation study against amyloid positron emission tomography. <i>JAMA Neurology</i> , 2014 , 71, 1282-9 ^{17.2}	17.2	254
462	CSF A β 2/A β 0 and A β 2/A β 8 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 154-65	5.3	244
461	Blood-based NFL: A biomarker for differential diagnosis of parkinsonian disorder. <i>Neurology</i> , 2017 , 88, 930-937	6.5	240
460	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
459	Cerebrospinal fluid analysis detects cerebral amyloid- β accumulation earlier than positron emission tomography. <i>Brain</i> , 2016 , 139, 1226-36	11.2	229
458	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
457	Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 316-20	2.6	204
456	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1180-90	1.2	201
455	Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 8727-32	11.5	200
454	Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 357-67	5.6	197
453	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015 , 85, 1240-9	6.5	192
452	Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. <i>International Journal of Cancer</i> , 2000 , 89, 251-8	7.5	181
451	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , 2019 , 18, 573-586	24.1	180
450	Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells. <i>Journal of Neuroscience</i> , 1998 , 18, 10277-86	6.6	179

449	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1151-1162	27.4	173
448	Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. <i>Brain, Behavior, and Immunity</i> , 2013 , 33, 183-9	16.6	166
447	Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. <i>Archives of Neurology</i> , 2008 , 65, 1102-7		162
446	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β Amyloid Status. <i>JAMA Neurology</i> , 2019 , 76, 1060-1069	17.2	159
445	CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. <i>PLoS ONE</i> , 2012 , 7, e30525	3.7	158
444	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , 2010 , 1362, 13-22	3.7	156
443	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016 , 8, 1184-1196	12	152
442	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014 , 9, 53	19	150
441	Fluid biomarkers in Alzheimer's disease - current concepts. <i>Molecular Neurodegeneration</i> , 2013 , 8, 20	19	147
440	Advantages and disadvantages of the use of the CSF Amyloid β (A β)42/40 ratio in the diagnosis of Alzheimer's Disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 34	9	145
439	CSF biomarkers predict a more malignant outcome in Alzheimer disease. <i>Neurology</i> , 2010 , 74, 1531-7	6.5	141
438	Systematic development of small molecules to inhibit specific microscopic steps of A β 2 aggregation in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E200-E208	11.5	134
437	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 1683	17.4	133
436	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012 , 78, 468-76	6.5	133
435	Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. <i>PLoS ONE</i> , 2012 , 7, e47387	3.7	131
434	Levels of cerebrospinal fluid β synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 25	9	130
433	CSF biomarkers and clinical progression of Parkinson disease. <i>Neurology</i> , 2015 , 84, 57-63	6.5	126
432	Associations between tau, A β and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019 , 92, e601-e612	6.5	125

431	F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1212-1223	12	124
430	βAmyloid peptides and amyloid plaques in Alzheimer's disease. <i>Neurotherapeutics</i> , 2015 , 12, 3-11	6.4	121
429	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018 , 91, e867-e877	6.5	120
428	Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 118-24	2.6	120
427	18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. <i>Brain</i> , 2016 , 139, 2372-9	11.2	120
426	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 2612	17.4	118
425	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. <i>European Journal of Neuroscience</i> , 2001 , 14, 1492-504	3.5	117
424	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <i>Neurobiology of Aging</i> , 2017 , 51, 104-112	5.6	115
423	Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 12-20	5.3	115
422	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019 , 11, e11170	12	113
421	Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. <i>Brain Research</i> , 2003 , 970, 47-57	3.7	106
420	Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. <i>Archives of Neurology</i> , 2007 , 64, 366-70		104
419	Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. <i>Neurology</i> , 2013 , 80, 829-38	6.5	103
418	Low CSF levels of both βsynuclein and the βsynuclein cleaving enzyme neurosin in patients with synucleinopathy. <i>PLoS ONE</i> , 2013 , 8, e53250	3.7	102
417	Amyloid blood biomarker detects Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	100
416	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , 2020 , 19, 951-962	24.1	95
415	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. <i>Brain</i> , 2017 , 140, 2286-2294	11.2	94
414	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 1119-28	4.3	94

413	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. <i>Movement Disorders</i> , 2016 , 31, 898-905	7	94
412	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
411	Increased basal ganglia binding of F-AV-1451 in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2017 , 32, 108-114	7	93
410	Evaluating amyloid- β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e66381	3.7	93
409	Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 45-53	4.3	91
408	Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches-Twenty years of research and development. <i>Forensic Science International: Genetics</i> , 2015 , 18, 100-17	4.3	90
407	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 40	9	90
406	Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. <i>NeuroMolecular Medicine</i> , 2011 , 13, 151-9	4.6	89
405	A β deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020 , 6, eaaz2387	14.3	88
404	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. <i>Brain</i> , 2017 , 140, 98-117	11.2	88
403	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2	15.2	86
402	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. <i>Acta Neuropathologica</i> , 2014 , 127, 633-43	14.3	86
401	A selected reaction monitoring (SRM)-based method for absolute quantification of A β 8, A β 0, and A β 2 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 1021-32	4.3	86
400	Soluble TNF receptors are associated with A β metabolism and conversion to dementia in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 1877-84	5.6	85
399	Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. <i>European Neurology</i> , 2010 , 63, 326-30	2.1	85
398	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 403-10	3.9	83
397	A β 0 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. <i>PLoS ONE</i> , 2010 , 5, e15725	3.7	82
396	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 347	17.4	81

395	Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. <i>Brain Research</i> , 2000 , 857, 20-9	3.7	81
394	Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021 , 27, 871-881	50.5	81
393	In vivo retention of F-AV-1451 in corticobasal syndrome. <i>Neurology</i> , 2017 , 89, 845-853	6.5	79
392	Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. <i>PLoS ONE</i> , 2012 , 7, e29868	3.7	79
391	Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts. <i>Experimental Neurology</i> , 1999 , 160, 279-88	5.7	79
390	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019 , 137, 279-296	14.3	79
389	Amyloid- β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 171-6	4.3	78
388	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 41	9	78
387	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1834-42	6.5	75
386	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 17	9	75
385	Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018 , 84, 729-740	9.4	74
384	Clinical validity of cerebrospinal fluid A β 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 196-213	5.6	73
383	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. <i>European Journal of Neuroscience</i> , 2001 , 13, 206-10	3.5	73
382	Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. <i>Archives of Neurology</i> , 2010 , 67, 217-23		72
381	Pleiotropic effects of GIP on islet function involve osteopontin. <i>Diabetes</i> , 2011 , 60, 2424-33	0.9	72
380	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , 2020 , 77, 955-965	17.2	71
379	Staging β Amyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2019 , 76, 1319-1329	17.2	71
378	Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. <i>Human Brain Mapping</i> , 2019 , 40, 2529-2545	5.9	69

377	Additive effects of caspase inhibitor and lazardoid on the survival of transplanted rat and human embryonic dopamine neurons. <i>Experimental Neurology</i> , 2000 , 164, 102-11	5.7	69
376	Biomarkers for neurodegenerative diseases. <i>Nature Medicine</i> , 2021 , 27, 954-963	50.5	69
375	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. <i>JAMA Neurology</i> , 2017 , 74, 1492-1501	17.2	67
374	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 58, 14-29	5.6	66
373	Plasma amyloid- β and risk of Alzheimer's disease in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 249-57.e1	1.2	66
372	Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010 , 5, 2	19	66
371	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. <i>PLoS ONE</i> , 2015 , 10, e0135458	3.7	66
370	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. <i>Brain</i> , 2018 , 141, 2755-2771	11.2	65
369	An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. <i>Journal of Proteome Research</i> , 2015 , 14, 654-63	5.6	65
368	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. <i>JAMA Psychiatry</i> , 2014 , 71, 1183-91	14.5	65
367	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. <i>Neurobiology of Aging</i> , 2010 , 31, 215-23	5.6	65
366	Link between GIP and osteopontin in adipose tissue and insulin resistance. <i>Diabetes</i> , 2013 , 62, 2088-94	0.9	64
365	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020 , 143, 3234-3241	11.4	63
364	Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018 , 90, e388-e395	6.5	62
363	Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 537-46	4.3	62
362	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 149-156	17.2	62
361	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1313-1333	1.2	61
360	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 1405-12	3.9	61

359	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009 , 30, 165-73	5.6	61
358	Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. <i>PLoS ONE</i> , 2009 , 4, e6294	3.7	60
357	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. <i>Brain</i> , 2020 , 143, 1233-1248	11.2	59
356	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. <i>Scientific Reports</i> , 2018 , 8, 13276	4.9	59
355	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 169	7.3	58
354	Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2015 , 10, e0141825	3.7	58
353	Reference measurement procedure for CSF amyloid beta (A β) and the CSF A β /A β ratio - a cross-validation study against amyloid PET. <i>Journal of Neurochemistry</i> , 2016 , 139, 651-658	6	56
352	Factors associated with fear of falling in people with Parkinson's disease. <i>BMC Neurology</i> , 2014 , 14, 19	3.1	56
351	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. <i>PLoS ONE</i> , 2012 , 7, e38639	3.7	56
350	LifeTime and improving European healthcare through cell-based interceptive medicine. <i>Nature</i> , 2020 , 587, 377-386	50.4	56
349	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021 , 27, 1034-1042	50.5	56
348	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010 , 2, 20	9	54
347	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2011 , 3, 1	5.3	53
346	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017 , 59, 1-9	5.6	52
345	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013 , 38, 1729-37	5	51
344	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
343	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2017 , 133, 149-151	14.3	50
342	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A β (1-42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> , 2019 , 9, 19024	4.9	50

341	Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. <i>JAMA Neurology</i> , 2019 , 76, 310-317	17.2	50
340	Apathy and anxiety are early markers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 85, 74-82	5.6	50
339	Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 625-36	4.3	49
338	Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 1223-30	4.3	49
337	Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. <i>Neurology</i> , 2016 , 86, 1754-61	6.5	48
336	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1145-1156	1.2	48
335	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. <i>Frontiers in Neuroscience</i> , 2017 , 11, 167	5.1	47
334	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017 , 11, 281	5.1	47
333	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012 , 119, 789-97	4.3	47
332	Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 623-631	8.9	46
331	Electroencephalogram variability in dementia with lewy bodies, Alzheimer's disease and controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 284-90	2.6	46
330	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , 2019 , 18, 1034-1044	24.1	45
329	Prediction of falls and/or near falls in people with mild Parkinson's disease. <i>PLoS ONE</i> , 2015 , 10, e0117018	3.7	45
328	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. <i>Journal of Neurochemistry</i> , 2001 , 78, 694-703	6	45
327	Increased midlife triglycerides predict brain amyloid and tau pathology 20 years later. <i>Neurology</i> , 2018 , 90, e73-e81	6.5	44
326	Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 570-580	1.2	43
325	Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid A β 2 and the Ratios of A β Isoforms Using Low Protein Binding Tubes. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 1121-32	4.3	43
324	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , 2021 , 20, 739-752	24.1	43

323	Relationship between cortical iron and tau aggregation in Alzheimer's disease. <i>Brain</i> , 2020 , 143, 1341-1349	4.2	42
322	A CASE OF XXXXY SEX CHROMOSOME ANOMALY WITH AUTORADIOGRAPHIC STUDIES. <i>Cytogenetic and Genome Research</i> , 1963 , 2, 208-31	1.9	42
321	Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 131, 269-78	6.5	41
320	Extensive changes in the transcriptional profile of human adipose tissue including genes involved in oxidative phosphorylation after a 6-month exercise intervention. <i>Acta Physiologica</i> , 2014 , 211, 188-200	5.6	41
319	Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. <i>Journal of Proteome Research</i> , 2014 , 13, 1077-87	5.6	41
318	Cerebral white matter lesions - associations with A β isoforms and amyloid PET. <i>Scientific Reports</i> , 2016 , 6, 20709	4.9	41
317	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 226-235	5.3	40
316	F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018 , 8, 4717	4.9	40
315	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019 , 93, e322-e335	3.5	40
314	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology</i> , 2021 ,	24.1	40
313	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral β amyloidosis. <i>Nature Communications</i> , 2016 , 7, 10918	17.4	39
312	Soluble amyloid precursor protein and β in CSF in Alzheimer's disease. <i>Brain Research</i> , 2013 , 1513, 117-263	3.7	38
311	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 1599-608	5.6	38
310	The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2008 , 23, 192-8	3.9	38
309	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , 2019 , 48, 912-925	7.8	38
308	Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019 , 72, 30-38	3.5	37
307	NG2 cells, a new trail for Alzheimer's disease mechanisms?. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 7	7.3	37
306	Evaluation of the cerebrospinal fluid amyloid- β -42/amyloid- β -40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 99-110	2.6	37

305	Evaluation of plasma Aβ ₄₂ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 231-8	4.3	37
304	Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. <i>Psychoneuroendocrinology</i> , 2013 , 38, 853-62	5	37
303	Evolution of Aβ ₄₂ and Aβ ₄₀ levels and Aβ ₄₂ /Aβ ₄₀ ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. <i>Journal of Nutrition, Health and Aging</i> , 2009 , 13, 205-8	5.2	37
302	Trace DNA collection: Performance of minitape and three different swabs. <i>Forensic Science International: Genetics Supplement Series</i> , 2009 , 2, 189-190	0.5	37
301	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020 , 11, 619	17.4	37
300	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2020 , 77, 632-642	17.2	36
299	Prevalence of the apolipoprotein E ε4 allele in amyloid τ-positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
298	Assessing risk for preclinical β-amyloid pathology with , cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 4, 76-84	5.2	36
297	Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 77	9	36
296	Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e81989	3.7	36
295	Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study. <i>Experimental Gerontology</i> , 2012 , 47, 179-82	4.5	35
294	FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. <i>Experimental Neurology</i> , 2000 , 164, 94-101	5.7	35
293	Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies. <i>Nature Structural and Molecular Biology</i> , 2020 , 27, 1125-1133	17.6	35
292	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 68	9	35
291	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , 2020 , 94, e2235-e2244	3.5	34
290	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. <i>BMC Neurology</i> , 2014 , 14, 64	3.1	34
289	CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2009 , 30, 1265-71	5.6	34
288	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. <i>European Journal of Neuroscience</i> , 2001 , 14, 1425-35	3.5	34

287	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021 , 1, 114-123		34
286	Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021 , 144, 310-324	11.2	34
285	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 13333	4.9	33
284	Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding. <i>Magnetic Resonance in Medicine</i> , 2020 , 84, 1605-1623	4.4	33
283	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1737-1741	4.4	33
282	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020 , 143, 650-660	11.2	33
281	Head-to-head comparison of tau positron emission tomography tracers [18 F]flortaucipir and [18 F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 342-354	8.8	33
280	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. <i>Neuroradiology</i> , 2015 , 57, 1079-91	3.2	32
279	Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 673-9	4.3	32
278	Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia. <i>Experimental Brain Research</i> , 2004 , 154, 442-9	2.3	32
277	No diagnostic value of plasma clusterin in Alzheimer's disease. <i>PLoS ONE</i> , 2012 , 7, e50237	3.7	32
276	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021 , 11, 76	8.6	32
275	Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. <i>Progress in Brain Research</i> , 2000 , 127, 203-31	2.9	31
274	Flunarizine improves the survival of grafted dopaminergic neurons. <i>Neuroscience</i> , 1999 , 94, 17-20	3.9	31
273	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, 335-344	1.2	31
272	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2140-2156	8.8	31
271	Accurate risk estimation of β amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019 , 15, 194-204	1.2	31
270	Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021 ,	11.2	31

269	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013 , 38, 1058-66	5	30
268	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. <i>Neuroscience Letters</i> , 2009 , 450, 56-9	3.3	30
267	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. <i>PLoS ONE</i> , 2016 , 11, e0157755	3.7	29
266	Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia. <i>Annals of Neurology</i> , 2020 , 87, 52-62	9.4	29
265	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. <i>JAMA Neurology</i> , 2021 , 78, 961-971	17.2	29
264	Head-to-Head Comparison of 8 Plasma Amyloid- β 2/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 1375-1382	17.2	29
263	Autocatalytic amplification of Alzheimer-associated A β 2 peptide aggregation in human cerebrospinal fluid. <i>Communications Biology</i> , 2019 , 2, 365	6.7	28
262	Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: candidate marker of brain health. <i>Journal of Alzheimer's Disease</i> , 2013 , 36, 739-47	4.3	28
261	Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy. <i>PLoS ONE</i> , 2013 , 8, e62354	3.7	28
260	Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 28, 314-9	2.6	28
259	Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 638-47	3.9	28
258	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 339-43	4.3	28
257	Engineered antibodies: new possibilities for brain PET?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2848-2858	8.8	27
256	Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. <i>Neurodegenerative Diseases</i> , 2008 , 5, 268-76	2.3	27
255	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019 , 8,	8.9	27
254	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 82	9	26
253	Towards a unified protocol for handling of CSF before β amyloid measurements. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 63	9	26
252	CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. <i>Molecular Psychiatry</i> , 2014 , 19, 148-9	15.1	26

251	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. <i>Science Advances</i> , 2020 , 6,	14.3	26
250	Expression of phosphofructokinase in skeletal muscle is influenced by genetic variation and associated with insulin sensitivity. <i>Diabetes</i> , 2014 , 63, 1154-65	0.9	25
249	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. <i>Cerebrovascular Diseases Extra</i> , 2015 , 5, 41-51	2.1	25
248	Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 1435-41	4.3	25
247	A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010 , 2, 29	9	25
246	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019 , 5, 7	9.7	24
245	Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. <i>PLoS ONE</i> , 2013 , 8, e66022	3.7	24
244	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases. <i>EuPA Open Proteomics</i> , 2015 , 8, 137-143	0.1	23
243	Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 556-63	4.6	23
242	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021 , 12, 3555	17.4	23
241	The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease. <i>PLoS ONE</i> , 2017 , 12, e0185239	3.7	22
240	Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. <i>Psychiatry Research - Neuroimaging</i> , 2018 , 275, 5-13	2.9	22
239	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and A β Pathology in Non-demented Individuals. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 306	5.3	22
238	Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 408-16	2.6	22
237	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. <i>BMC Neurology</i> , 2020 , 20, 10	3.1	22
236	Soluble P-tau ²¹⁷ reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14022	12	22
235	Preclinical Amyloid- β and Axonal Degeneration Pathology in Delirium. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 371-379	4.3	22
234	Cognitive and functional changes associated with A β pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016 , 48, 172-181	5.6	22

233	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2018 , 28, 3638-3649	5.1	21
232	Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 471-8	4.3	21
231	Altered structural network organization in cognitively normal individuals with amyloid pathology. <i>Neurobiology of Aging</i> , 2018 , 64, 15-24	5.6	20
230	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 2	9	20
229	A fast analysis system for forensic DNA reference samples. <i>Forensic Science International: Genetics</i> , 2008 , 2, 184-9	4.3	20
228	External validation of a 3-step Falls prediction model in mild Parkinson's disease. <i>Journal of Neurology</i> , 2016 , 263, 2462-2469	5.5	20
227	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017 , 11, 1700100	3.1	19
226	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. <i>Cerebral Cortex</i> , 2019 , 29, 2173-2182	5.1	19
225	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2013 , 28, 738-44	3.9	19
224	A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 1353-63	4.3	19
223	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. <i>Hippocampus</i> , 2017 , 27, 653-667	3.5	18
222	Method comparison study of the Elecsys® β Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019 , 72, 7-14	3.5	18
221	F-Flortaucipir in TDP-43 associated frontotemporal dementia. <i>Scientific Reports</i> , 2019 , 9, 6082	4.9	18
220	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020 , 139, 104831	7.5	18
219	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. <i>Neuroradiology</i> , 2018 , 60, 247-254	3.2	18
218	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. <i>Cerebral Cortex</i> , 2018 , 28, 340-349	5.1	18
217	The clinical significance of 10-m walk test standardizations in Parkinson's disease. <i>Journal of Neurology</i> , 2018 , 265, 1829-1835	5.5	18
216	Telomere length in blood and skeletal muscle in relation to measures of glycaemia and insulinaemia. <i>Diabetic Medicine</i> , 2012 , 29, e377-81	3.5	18

215	Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013 , 3, 113-22	2.5	18
214	Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. <i>Biological Psychiatry</i> , 2011 , 70, 145-51	7.9	18
213	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 206-13	3.9	18
212	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020 , 143, 3805-3815	11.2	18
211	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2121-2139	8.8	18
210	Amyloid pathology in the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018 , 64, 76-84	5.6	17
209	Converging pathways of chromogranin and amyloid metabolism in the brain. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 1039-49	4.3	17
208	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 95, 143-153	5.6	17
207	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019 , 40, 638-651	5.9	17
206	Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study. <i>Journal of Internal Medicine</i> , 2017 , 282, 94-101	10.8	16
205	Preclinical effects of APOE ϵ 4 on cerebrospinal fluid A β 2 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 87	9	16
204	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 403-11	5.2	16
203	First-degree relatives of type 2 diabetic patients have reduced expression of genes involved in fatty acid metabolism in skeletal muscle. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1332-7	5.6	16
202	Cerebrospinal Fluid Levels of sAPP β and sAPP γ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011 , 2011, 495025	3.7	16
201	Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell line-derived neurotrophic factor. <i>Cell Transplantation</i> , 2000 , 9, 577-84	4	16
200	Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. <i>Neurology</i> , 2019 , 92, e395-e405	6.5	16
199	Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process. <i>International Journal of Legal Medicine</i> , 2017 , 131, 303-317	3.1	15
198	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020 , 11, 6252	17.4	15

197	βAmyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , 2019 , 9, 11180	4.9	15
196	Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease. <i>International Psychogeriatrics</i> , 2015 , 27, 1401-9	3.4	15
195	Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 203-11	2.6	15
194	Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 544-52	2.6	15
193	The A4 study: βAmyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 776-785	5.3	15
192	βSynuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 15226-15235	11.5	14
191	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1661-1673	5.3	14
190	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2021 , 34, 266-274	7.1	14
189	Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2097-2109	8.8	14
188	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 997-1004	5.5	13
187	Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. <i>Alzheimer's and Dementia</i> , 2018 , 14, 54-61	1.2	13
186	STR-validator: an open source platform for validation and process control. <i>Forensic Science International: Genetics</i> , 2014 , 13, 154-66	4.3	13
185	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 63	9	13
184	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020 , 95, e3026-e3035	6.5	13
183	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, βSynuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40). <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 40	9	12
182	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	12
181	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020 , 134, 104645	7.5	12
180	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1575-1582	1.2	12

179	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021 , 144, 2826-2836	11.2	12
178	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β 2/A β 0 and p-tau. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	12
177	Characterisation of artefacts and drop-in events using STR-validator and single-cell analysis. <i>Forensic Science International: Genetics</i> , 2017 , 30, 57-65	4.3	11
176	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 19	9	11
175	Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 87	9	11
174	Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 343-50	4.3	11
173	No independent association between pulse wave velocity and dementia: a population-based, prospective study. <i>Journal of Hypertension</i> , 2017 , 35, 2462-2467	1.9	11
172	Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. <i>Movement Disorders</i> , 2020 , 35, 513-518		11
171	A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2295-2305	8.8	11
170	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1081-1103	1.2	10
169	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 9	9	10
168	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from β Synucleinopathies. <i>Radiology</i> , 2019 , 293, 646-653	20.5	10
167	A β -15/16 as a potential diagnostic marker in neurodegenerative diseases. <i>NeuroMolecular Medicine</i> , 2013 , 15, 169-79	4.6	10
166	CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 33, 156-63	2.6	10
165	Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment. <i>Journal of Neural Transmission</i> , 2012 , 119, 821-31	4.3	10
164	A comparison of three automated DNA purification methods in Forensic casework. <i>Forensic Science International: Genetics Supplement Series</i> , 2008 , 1, 76-77	0.5	10
163	Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation. <i>NeuroReport</i> , 1999 , 10, 3347-51	1.7	10
162	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.. <i>JAMA Neurology</i> , 2021 ,	17.2	10

161	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021 , 144, 2771-2783	11.2	10
160	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2070-2085	8.8	10
159	Association Between Apolipoprotein E ϵ vs ϵ , Age, and β Amyloid in Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021 , 78, 229-235	17.2	10
158	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021 , 97, e1681-e1694	6.5	10
157	Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease. <i>PLoS ONE</i> , 2019 , 14, e0222002	3.7	9
156	Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease. <i>PLoS ONE</i> , 2019 , 14, e0218561	3.7	9
155	Less pronounced response to exercise in healthy relatives to type 2 diabetic subjects compared with controls. <i>Journal of Applied Physiology</i> , 2015 , 119, 953-60	3.7	9
154	European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 538-549	5.2	9
153	Flt3 ligand does not differentiate between Parkinsonian disorders. <i>Movement Disorders</i> , 2014 , 29, 1319-22		9
152	Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents. <i>Experimental Neurology</i> , 2003 , 183, 430-7	5.7	9
151	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
150	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 109	9	9
149	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 259-265	5.3	9
148	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. <i>Scientific Reports</i> , 2021 , 11, 1965	4.9	9
147	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2110-2120	8.8	9
146	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12137	5.2	9
145	Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes. <i>Molecular and Cellular Endocrinology</i> , 2017 , 447, 52-60	4.4	8
144	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 1213-1220	4.3	8

143	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. <i>Scientific Reports</i> , 2019 , 9, 6079	4.9	8
142	Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. <i>Movement Disorders</i> , 2020 , 35, 1258-1263	7	8
141	The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls. <i>Quality of Life Research</i> , 2016 , 25, 2571-2577	3.7	8
140	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 71, 81-90	5.6	8
139	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. <i>Neurodegenerative Diseases</i> , 2015 , 15, 331-8	2.3	8
138	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. <i>Clinical Endocrinology</i> , 2011 , 75, 301-8	3.4	8
137	The usefulness of cube copying for evaluating treatment of Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008 , 23, 439-46	2.5	8
136	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e193-e202	6.5	8
135	Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. <i>Annals of Neurology</i> , 2020 , 88, 878-892	9.2	8
134	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	8
133	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14398	12	8
132	Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. <i>Lancet Neurology</i> , 2016 , 15, 650-651	24.1	8
131	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ϵ 4, sex and age. <i>Progress in Neurobiology</i> , 2021 , 198, 101904	10.9	8
130	Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. <i>Movement Disorders</i> , 2021 , 36, 767-771	7	8
129	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2245-2258	8.8	8
128	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 19	7.3	8
127	A porous silicon immunoassay platform for fluorometric determination of β -synuclein in human cerebrospinal fluid. <i>Mikrochimica Acta</i> , 2014 , 181, 1143-1149	5.8	7
126	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	7

125	Parkinson's disease: evolution of cognitive impairment and CSF A β profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 165-170	5.5	7
124	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. <i>Nutrition Research</i> , 2018 , 60, 13-25	4	7
123	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.. <i>journal of prevention of Alzheimer's disease, The</i> , 2022 , 9, 197-210	3.8	7
122	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.. <i>Neurology</i> , 2021 ,	6.5	7
121	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021 , e14408	12	7
120	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 327-332	5.2	6
119	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 30	9	6
118	Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?. <i>Brain</i> , 2018 , 141, 1241-1244	11.2	6
117	Diagnostic value of plasma neurofilament light: A multicentre validation study		6
116	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. <i>Pain</i> , 2020 , 161, 2142-2154	8	6
115	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2020 , 93, 1-15	5.6	6
114	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 27-31	4.3	5
113	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. <i>NeuroImage: Clinical</i> , 2020 , 27, 102310	5.3	5
112	Regional times to equilibria and their impact on semi-quantification of [F]AV-1451 uptake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 2223-2232	7.3	5
111	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 158-165	3.6	5
110	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. <i>Scientific Reports</i> , 2019 , 9, 15417	4.9	5
109	N-Terminal Prosomatostatin and Risk of Vascular Dementia. <i>Cerebrovascular Diseases</i> , 2017 , 44, 259-265	3.2	5
108	Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. <i>Fluids and Barriers of the CNS</i> , 2015 , 12, 22	7	5

107	Characterizing the spatiotemporal variability of Alzheimer’s disease pathology		5
106	Kinetic fingerprints differentiate anti-A β therapies		5
105	Time between milestone events in the Alzheimer’s disease amyloid cascade. <i>NeuroImage</i> , 2021 , 227, 117676	7.9	5
104	Sex differences in off-target binding using tau positron emission tomography. <i>NeuroImage: Clinical</i> , 2021 , 31, 102708	5.3	5
103	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. <i>Neuroradiology</i> , 2019 , 61, 397-404	3.2	4
102	CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 863-872	5.3	4
101	CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ϵ carriers. <i>Scientific Reports</i> , 2020 , 10, 8233	4.9	4
100	Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. <i>Vascular Pharmacology</i> , 2020 , 125-126, 106649	5.9	4
99	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. <i>Nordic Journal of Psychiatry</i> , 2017 , 71, 477-484	2.3	4
98	Evaluation of GeneMapper π ID-X Mixture Analysis tool. <i>Forensic Science International: Genetics Supplement Series</i> , 2011 , 3, e11-e12	0.5	4
97	Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.. <i>Acta Neuropathologica Communications</i> , 2022 , 10, 3	7.3	4
96	The accuracy and robustness of plasma biomarker models for amyloid PET positivity.. <i>Alzheimer’s Research and Therapy</i> , 2022 , 14, 26	9	4
95	Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease		4
94	Image reconstruction methods affect software-aided assessment of pathologies of [F]flutemetamol and [F]FDG brain-PET examinations in patients with neurodegenerative diseases. <i>NeuroImage: Clinical</i> , 2020 , 28, 102386	5.3	4
93	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2086-2096	8.8	4
92	The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster A β -associated tau accumulation and cognitive decline. <i>Alzheimer’s and Dementia</i> , 2021 ,	1.2	4
91	Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?. <i>Brain</i> , 2016 , 139, e61	11.2	4
90	Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. <i>Journal of Parkinson’s Disease</i> , 2016 , 6, 99-108	5.3	4

89	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 38	9	4
88	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 138	9	4
87	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2259-2271	8.8	4
86	The protective gene dose effect of the APOE ϵ allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	4
85	High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study. <i>Scientific Reports</i> , 2020 , 10, 8027	4.9	3
84	Cerebrospinal fluid A β 2/A β 0 and A β 2/A β 8 as biomarkers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016 , 39, S28	5.6	3
83	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2017 , 7, e018177	3	3
82	Graft survival. <i>Journal of Neurosurgery</i> , 1999 , 90, 804-6	3.2	3
81	\square <i>Neurology</i> , 2022 ,	6.5	3
80	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	3
79	Derivation and utility of an A β PET pathology accumulation index to estimate A β load. <i>Neurology</i> , 2020 , 95, e2834-e2844	6.5	3
78	Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 158	9	3
77	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2183-2199	8.8	3
76	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2016 , 86, 1747-8	6.5	3
75	Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment. <i>European Radiology</i> , 2021 , 31, 666-673	8	3
74	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau		3
73	Subtypes of Alzheimer's disease: questions, controversy, and meaning.. <i>Trends in Neurosciences</i> , 2022 ,	13.3	3
72	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2017 , 140, e33	11.2	2

71	[IC-0205]: ABNORMAL STRUCTURAL BRAIN CONNECTOME IN INDIVIDUALS WITH PRECLINICAL ALZHEIMER'S DISEASE 2017 , 13, P7-P7		2
70	Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	2
69	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. <i>Scientific Reports</i> , 2019 , 9, 2460	4.9	2
68	Brain activity and Alzheimer's disease: a complex relationship. <i>Brain</i> , 2016 , 139, 2109-10	11.2	2
67	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2007 , 20, 233	4.4	2
66	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
65	The global Alzheimer's Association round robin study on plasma amyloid β methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12242	5.2	2
64	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021 , 18, 573-584	3	2
63	Forensic genetics: the basics 2020 , 1-53		2
62	Plasma glial fibrillary acidic protein is an early marker of A β pathology in Alzheimer's disease		2
61	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. <i>Psychiatry Research - Neuroimaging</i> , 2021 , 312, 111273	2.9	2
60	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 , 76, 683-691	6.4	2
59	SCRT1 is a novel beta cell transcription factor with insulin regulatory properties. <i>Molecular and Cellular Endocrinology</i> , 2021 , 521, 111107	4.4	2
58	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures		2
57	Association of CSF A β 8 Levels With Risk of Alzheimer Disease-Related Decline.. <i>Neurology</i> , 2021 ,	6.5	2
56	Tau PET Imaging in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022 , 63, 20S-26S	8.9	2
55	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease. <i>BMC Neurology</i> , 2015 , 15, 8	3.1	1
54	Modeling patient-specific tau spreading patterns in Alzheimer's disease: Towards precision medicine. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040587	1.2	1

53	The accumulation rate of tau aggregates is higher in females and younger individuals. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043876	1.2	1
52	[18F]Flortaucipir distinguishes Alzheimer's disease from progressive supranuclear palsy pathology in a mixed-pathology case. <i>Acta Neuropathologica</i> , 2020 , 139, 411-413	14.3	1
51	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.. <i>Clinical Mass Spectrometry</i> , 2019 , 14 Pt B, 74-82	1.9	1
50	Free open source software for internal validation of forensic STR typing kits. <i>Forensic Science International: Genetics Supplement Series</i> , 2013 , 4, e300-e301	0.5	1
49	[P4152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β AMYLOID (1 β 2) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS 2017 , 13, P1316-P1317		1
48	Automatic data processing of reference DNA-profiles from FTA and non-FTA samples. <i>Forensic Science International: Genetics Supplement Series</i> , 2008 , 1, 29-31	0.5	1
47	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization.. <i>Pain Reports</i> , 2022 , 7, e988	3.5	1
46	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.. <i>Movement Disorders</i> , 2022 ,	7	1
45	Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment		1
44	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021 , 48674211058684	2.6	1
43	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. <i>Journal of Parkinson's Disease</i> , 2021 ,	5.3	1
42	Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease		1
41	A Deep Learning Approach to MR-less Spatial Normalization for Tau PET Images. <i>Lecture Notes in Computer Science</i> , 2019 , 355-363	0.9	1
40	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease		1
39	Time between milestone events in the Alzheimer's disease amyloid cascade		1
38	Empirical characterization of DNA profiles 2020 , 55-88		1
37	CSF A β 8 levels are associated with Alzheimer-related decline: implications for β secretase modulators		1
36	P3-267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS 2018 , 14, P1178-P1179		1

35	Genetic characterization of amyloid- β and tau network spread. <i>Nature Medicine</i> , 2018 , 24, 1790-1792	50.5	1
34	Management of Alzheimer's disease takes a leap forward. <i>Lancet Neurology</i> , 2021 , 20, 586-587	24.1	1
33	Tau pathology mediates age effects on medial temporal lobe structure. <i>Neurobiology of Aging</i> , 2021 , 109, 135-144	5.6	1
32	Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly		1
31	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 46	9	1
30	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. <i>Scientific Reports</i> , 2021 , 11, 19853	4.9	0
29	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1832-1842	1.2	0
28	P4-540: CSF PTAU-217 PERFORMS BETTER THAN PTAU-181 IN DETECTING ABNORMAL RETENTION OF 18F-FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS 2019 , 15, P1523-P1523		0
27	Biomarker testing in MCI patients-deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 14	9	0
26	Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 67	9	0
25	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine-use protocol for CSF collection. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047394	1.2	
24	P4-023: INCREASED LEVELS OF ANGIOGENIC FACTORS IN THE CEREBROSPINAL FLUID ARE ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PARKINSON'S DISEASE 2014 , 10, P791-P791		
23	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE 2014 , 10, P508-P508		
22	[IC-P-123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND A β PATHOLOGY IN NON-DEMENTED INDIVIDUALS 2017 , 13, P94-P94		
21	[P3032]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY 2017 , 13, P985-P985		
20	[P3002]: PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMYLOID PATHOLOGY EXHIBIT SIGNIFICANT BRAIN ATROPHY, TAU PATHOLOGY AND MILD MEMORY DIFFICULTIES 2017 , 13, P1117-P1117		
19	[P4097]: EMERGING AMYLOID PATHOLOGY 2017 , 13, P1340-P1340		
18	[P1050]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN IL1RAP AND ALZHEIMER'S-RELATED CSF-BIOMARKERS 2017 , 13, P300-P300		

- 17 [IC-P-098]: ASSOCIATION BETWEEN CEREBROSPINAL FLUID AND PLASMA NEURODEGENERATION BIOMARKERS WITH BRAIN ATROPHY IN ALZHEIMER'S DISEASE **2017**, 13, P75-P75
- 16 [IC-P-199]: [18]F-AV-1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION **2017**, 13, P146-P147
- 15 [P2046]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES **2017**, 13, P706-P707
- 14 Components of gait in people with and without mild cognitive impairment.. *Gait and Posture*, **2022**, 93, 83-89 2.6
- 13 Allele drop-out and the stochastic threshold **2020**, 89-110
- 12 Low-template DNA **2020**, 111-128
- 11 A qualitative (semi-continuous) model: LRmix Studio **2020**, 153-179
- 10 Investigative forensic genetics: SmartRank, CaseSolver and DNAmatch2 **2020**, 339-383
- 9 P4-339: Early- and Late-Onset Alzheimer's Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]F-AV-1451 TAU Positron Emission Tomography **2016**, 12, P1164-P1165
- 8 P4-531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO AMYLOID POSITIVITY **2019**, 15, P1517-P1519
- 7 DT-01-04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER-2 STUDY **2019**, 15, P1485-P1486
- 6 P3-413: HETEROGENEOUS TAU-PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY **2018**, 14, P1263-P1264
- 5 IC-P-224: HETEROGENEOUS TAU-PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY **2018**, 14, P182-P183
- 4 O2-09-02: A UNIFIED PRE-ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS **2018**, 14, P641-P641
- 3 IC-P-036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NON-DEMENTED ELDERLY SUBJECTS **2018**, 14, P39-P39
- 2 Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience. *European Radiology*, **2021**, 1 8
- 1 Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e055011 1.2